Abstract
Septic arthritis is a rheumatologic emergency as joint destruction occurs rapidly and can lead to significant morbidity and mortality. Accurate diagnosis can be particularly challenging in patients with underlying inflammatory joint disease. This review outlines the risk factors for septic arthritis and summarizes the causative bacterial organisms. We highlight advances in antibiotic management with a focus on new drugs for methicillin-resistant Staphylococcus aureus (MRSA) and discuss the use of adjunctive therapies for treatment of septic arthritis in adults.
MeSH terms
-
Acetamides / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Arthritis, Infectious / diagnosis
-
Arthritis, Infectious / drug therapy*
-
Arthritis, Infectious / microbiology
-
Bacterial Infections / complications
-
Bacterial Infections / diagnosis
-
Bacterial Infections / drug therapy*
-
Ceftaroline
-
Cephalosporins / therapeutic use
-
Daptomycin / therapeutic use
-
Drug Therapy, Combination
-
Humans
-
Immunologic Factors / therapeutic use*
-
Linezolid
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification
-
Oxazolidinones / therapeutic use
-
Risk Factors
-
Staphylococcal Infections / complications
-
Staphylococcal Infections / diagnosis
-
Staphylococcal Infections / drug therapy
-
Treatment Outcome
-
Virginiamycin / therapeutic use
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Cephalosporins
-
Immunologic Factors
-
Oxazolidinones
-
Virginiamycin
-
quinupristin-dalfopristin
-
Linezolid
-
Daptomycin